Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06328673 · ClinicalTrials.gov registry record · Phase 1

A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by D2M Biotherapeutics.

Active
Registry status
Phase 1
Development phase
160
Enrollment target
2
Study locations

NCT06328673 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by D2M Biotherapeutics. The registered enrollment target is 160 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (17% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06328673, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by D2M Biotherapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
160 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to define a safe and effective dose of DM919 for participants with solid tumors The main questions it aims to answer are: What is the safe and effective dose of DM919 when used alone or in combination with pembrolizumab? What cancers can be treated effectively with DM919 alone or in combination with pembrolizumab?? Participants will be asked to attend clinic and be given a intravenous infusion of DM919 or DM-919 in combination with pembrolizumab. They will have blood tests and other assessments to measure whether DM-919 will have the effect on tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Pembrolizumab
  • DRUG DM919

Study Locations (2)

Texas

  • NEXT Oncology - San Antonio

Other

  • The Cancer Institute and Hospital, Chinese Academy of Medical Sciences(CAMS) - Beijing

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2024-04-09
Est. Completion 2026-03-01
Phase Phase 1

Sponsor

D2M Biotherapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06328673

The ClinicalTrials.gov registry entry for NCT06328673 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (17% lower). The listed sponsor is D2M Biotherapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT06328673 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Other.

Frequently Asked Questions

What is clinical trial NCT06328673 about?

NCT06328673 is a clinical study titled "A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors". The goal of this clinical trial is to define a safe and effective dose of DM919 for participants with solid tumors The main questions it aims to answer are: What is the safe and effective dose of DM919 when used alone or in combination with pembrolizumab? What cancers can be treated effectively wi...

What is the current status of trial NCT06328673?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2024-04-09. Estimated completion is 2026-03-01.

What conditions does trial NCT06328673 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06328673?

The interventions under investigation include: Pembrolizumab (DRUG), DM919 (DRUG).

Who is sponsoring clinical trial NCT06328673?

This trial is sponsored by D2M Biotherapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06328673 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.